Weil Company’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Weil Company’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-33,235	Closed	-$149K	–	154
2021 Q4	$149K	Sell	33,235 -20,000	-38%	-$94.9K	0.07%	139
2021 Q3	$259K	Sell	53,235 -1,672	-3%	-$9.21K	0.13%	120
2021 Q2	$374K	Hold	54,907	–	–	0.19%	104
2021 Q1	$388K	Sell	54,907 -50,000	-48%	-$360K	0.22%	92
2020 Q4	$657K	Buy	104,907 +720	+0.7%	+$4.24K	0.39%	61
2020 Q3	$564K	Buy	104,187 +50,431	+94%	+$250K	0.41%	60
2020 Q2	$281K	Buy	53,756 +25,000	+87%	+$111K	0.24%	78
2020 Q1	$91K	Buy	28,756 +5,006	+21%	+$18.5K	0.09%	88
2019 Q4	$96K	Buy	23,750 +3,750	+19%	+$13K	0.07%	110
2019 Q3	$86K	Buy	+20,000	New	+$80K	0.06%	149

Other funds holding PRTK

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

FIG

Fortress Investment Group New York $394M AUM 22.99% 1-Year Est. Return

Weil Company's PRTK Position: Q1 2022 in Review

Weil Company sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2022, closing a stake of 33,235 shares — an estimated $149K sold.

Weil Company first reported a position in PRTK in Q3 2019 and held it in 10 quarters. The position peaked at $657K in Q4 2020. 100 funds tracked by Wall St. Rank hold PRTK as of Q1 2022.

Weil Company reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
Weil Company sold 33,235 Paratek Pharmaceuticals, Inc. shares in Q1 2022, an estimated $149K.
Weil Company first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2019 and held it in 10 quarters.
Weil Company's Paratek Pharmaceuticals, Inc. position peaked at $657K in Q4 2020.
100 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2022.

Based on Weil Company's 13F filing for Q1 2022, filed 6 May 2022.